Sessions

Viral Vector Development: Safe and Effective Viral Vectors for Therapeutic Success
Changing the Cell Therapy Landscape with In-Vivo Therapies: Is this a Viable Alternative for Point of Care Therapeutics?
Achieving Best Practice in Quality Control and Assurance
Implementing New and Enabling Technologies into Existing Processes for Improved Commercial Outcomes
Implementing New and Enabling Technologies into Existing Processes for Improved Commercial Outcomes
Analytics, Data and IT Tech Solutions: An Overview of Best Practices and Technology
Delivery Solutions, Improvements and Alternatives for Gene & Cell Therapy
Industry 4.0 Approaches Transforming Cell and Gene Therapy
Accelerating the Digitalisation Revolution in Cell and Gene Therapy Development

Viral Vector Development: Safe and Effective Viral Vectors for Therapeutic Success

26 Jan 2022
11:00
SPONSORED BY
Oxford BioMedica (UK) Ltd
Corning Incorporated

11:00 Chairperson’s Opening
Nathalie Clement, Vice President of Vector Development for Translational Gene Therapies, Stealth Biotech

11:05 Meeting the Challenge of a Pandemic Response

Discover how Oxford Biomedica collaborated with the University of Oxford and AstraZeneca to help develop and manufacture the adenovirus-vectored vaccine ChAdOx1 nCoV-19 vaccine including:

  • Role of people (skills), capacity, capabilities and supply chains
  • Collaboration between academia and industry – tackling CMC challenges
  • Ensuring safety and regulatory requirements are satisfied – what a productive regulatory relationship looks like

James Miskin, Chief Technical Officer, Oxford Biomedica

11:25 Development of AAV for Use in Ex-vivo Cellular Therapy Applications (Live Streaming) 

  • An overview of CQA considerations for non-direct injected AAV products
  • Highlighting drivers for enriching for full AAV

Patrick Westmoreland, Principal Scientist, Viral Vector and Gene Editing Process Development, Bristol Myers Squibb

11:45 Efficient AAV Production Scale-up Enables Rapid Generation of High Throughput AI-designed AAV Libraries to Accelerate Gene Therapy Development

  • Success in gene therapy relies on the ability to safely and precisely deliver a genetic payload to the intended target cells. To enable the potential of Gene Therapy, novel, optimized capsids are needed
  • This presentation will describe a novel approach that combines next-gen library synthesis, next-gen sequencing, artificial intelligence, and novel fixed bed bioreactor technology to accelerate the production of improved indication specific AAV capsids, to deliver therapeutic transgenes
  • The speaker will share their strategy for efficiently scaling up high throughput AAV library production, including results from recent studies using the Corning® Ascent™ FBR fixed bed bioreactor technology

Chris Reardon, Associate Scientist, Dyno Therapeutics

12:05 Speaker Q&A and Panel Discussion

Speakers

Nathalie Clement
Associate Program Director & Associate Professor
Powell Gene Therapy Center
Patrick Westmoreland
Principal Scientist, Viral Vector and Gene Editing Process Development
Bristol Myer Squibb
Chris Reardon
Associate Scientist
Dyno Therapeutics